200 mg once daily. Patient w/o cirrhosis In combination w/ sofosbuvir for 12 wk. Patient w/ compensated cirrhosis In combination w/ sofosbuvir for 24 wk.
Not to be given as monotherapy. Patients w/ HCV genotypes 2, 4, 5 & 6; previously failed therapy w/ NS5A-containing regimen. HCV/HBV co-infection; perform HBV screening prior to initiation. Diabetic patients. Not to be taken by patients w/ fructose intolerance. Not recommended w/ concomitant use of moderate P-gp inducers eg, oxcarbazepine, rifapentine. May affect ability to drive & use machines. Renal impairment (>1.5 x ULN) or ESRD; severe hepatic impairment, decompensated cirrhosis; post-liver transplant patients. Women of childbearing potential should use effective contraception prior to & for 1 mth after last dose. Not recommended during pregnancy & lactation. Not recommended in childn & adolescents <18 yr. Elderly ≥65 yr.
Sign Out
